Nrf2-Mediated Antioxidant Response and Drug Efflux Transporters Upregulation as Possible Mechanisms of Resistance in Photodynamic Therapy of Cancers

References

• Mattiuzzi C, Lippi G. Current cancer epidemiology. J Epidemiol Glob Health. 2019;9(4):217–222. doi:10.2991/jegh.k.191008.001
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global health estimates 2016: disease burden by cause, age, sex, by country and by region, 2000–2016. World Health Organization. 2018; Geneva. Available from: https://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html. Accessed August 30, 2021.
   Google Scholar
• Kalubula M, Shen H, Makasa M, Liu L. Epidemiology of cancers in Zambia: a significant variation in cancer incidence and prevalence across the nation. Malawi Med J. 2021;33(3):186–195. doi:10.4314/mmj.v33i3.6
   PubMed Web of Science ®Google Scholar
• Kraybill WG, Harris J, Spiro IJ, et al. Long-term results of a Phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: radiation therapy oncology group trial 9514. Cancer. 2010;116(19):4613–4621. doi:10.1002/cncr.25350
   PubMed Web of Science ®Google Scholar
• Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res. 2014;3(4):242–249. doi:10.3978/j.issn.2218-6751.2013.12.05
   PubMedGoogle Scholar
• Mallick S, Benson R, Hakim A, Rath GK. Management of glioblastoma after recurrence: a changing paradigm. J Egypt Natl Cancer Inst. 2016;28(4):199–210. doi:10.1016/j.jnci.2016.07.001
   PubMed Web of Science ®Google Scholar
• Corrado G, Salutari V, Palluzzi E, Distefano MG, Scambia G, Ferrandina G. Optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther. 2017;17(12):1147–1158. doi:10.1080/14737140.2017.1398088
   PubMed Web of Science ®Google Scholar
• van der Merwe M, van Niekerk G, Fourie C, du Plessis M, Engelbrecht A-M. The impact of mitochondria on cancer treatment resistance. Cell Oncol. 2021;44(5):983–995. doi:10.1007/s13402-021-00623-y
   Web of Science ®Google Scholar
• Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219–234. doi:10.1038/nrd1984
   PubMed Web of Science ®Google Scholar
• Das CK, Mandal M, Kögel D. Pro-survival autophagy and cancer cell resistance to therapy. Cancer Metastasis Rev. 2018;37(4):749–766. doi:10.1007/s10555-018-9727-z
   PubMed Web of Science ®Google Scholar
• Nikolaou M, Pavlopoulou A, Georgakilas AG, Kyrodimos E. The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis. 2018;35(4):309–318. doi:10.1007/s10585-018-9903-0
   PubMed Web of Science ®Google Scholar
• de la Vega MR, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer. Cancer Cell. 2018;34(1):21–43. doi:10.1016/j.ccell.2018.03.022
   PubMed Web of Science ®Google Scholar
• Wu S, Lu H, Bai Y. Nrf2 in cancers: a double‐edged sword. Cancer Med. 2019;8(5):2252–2267. doi:10.1002/cam4.2101
   PubMed Web of Science ®Google Scholar
• Bai X, Chen Y, Hou X, Huang M, Jin J. Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters. Drug Metab Rev. 2016;48(4):541–567. doi:10.1080/03602532.2016.1197239
   PubMed Web of Science ®Google Scholar
• Cykowiac M, Krajka-kuzniak V. Role of Nrf2 in pancreatic cancer. Antioxidants. 2022;11(1):98. doi:10.3390/antiox11010098
   Web of Science ®Google Scholar
• Xue D, Zhou X, Qiu J. Emerging role of NRF2 in ROS-mediated tumor chemoresistance. Biomed Pharmacother. 2020;131:110676. doi:10.1016/j.biopha.2020.110676
   PubMed Web of Science ®Google Scholar
• Choi BH, Kim JM, Kwak MK. The multifaceted role of NRF2 in cancer progression and cancer stem cells maintenance. Arch Pharm Res. 2021;44(3):263–280. doi:10.1007/s12272-021-01316-8
   PubMed Web of Science ®Google Scholar
• Weijer R, Broekgaarden M, van Golen RF, et al. Low-power photodynamic therapy induces survival signaling in perihilar cholangiocarcinoma cells. BMC Cancer. 2015;15(1):1–17. doi:10.1186/s12885-015-1994-2
   PubMedGoogle Scholar
• Agostinis P, Berg K, Cengel KA, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61(4):250–281. doi:10.3322/caac.20114
   PubMed Web of Science ®Google Scholar
• Baldea I, Filip AG. Photodynamic therapy in melanoma-An update. J Physiol Pharmacol. 2012;63(2):109–118.
   PubMed Web of Science ®Google Scholar
• Van Straten D, Mashayekhi V, De Bruijn HS, Oliveira S, Robinson DJ. Oncologic photodynamic therapy: basic principles, current clinical status and future directions. Cancers. 2017;9(2):19. doi:10.3390/cancers9020019
   PubMed Web of Science ®Google Scholar
• Manda G, Hinescu ME, Neagoe IV, et al. Emerging therapeutic targets in oncologic photodynamic therapy. Curr Pharm Des. 2018;24(44):5268–5295. doi:10.2174/1381612825666190122163832
   PubMed Web of Science ®Google Scholar
• Rapozzi V, D’Este F, Xodo LE. Molecular pathways in cancer response to photodynamic therapy. J Porphyr Phthalocyanines. 2019;23(04n05):410–418. doi:10.1142/S1088424619300064
   Google Scholar
• Martins WK, Belotto R, Silva MN, et al. Autophagy regulation and photodynamic therapy: insights to improve outcomes of cancer treatment. Front Oncol. 2021;10:610472. doi:10.3389/fonc.2020.610472
   PubMed Web of Science ®Google Scholar
• Manda G, Isvoranu G, Comanescu MV, Manea A, Butuner BD, Korkmaz KS. The redox biology network in cancer pathophysiology and therapeutics. Redox Biol. 2015;5:347–357. doi:10.1016/j.redox.2015.06.014
   PubMed Web of Science ®Google Scholar
• Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8(7):579–591. doi:10.1038/nrd2803
   PubMed Web of Science ®Google Scholar
• Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 2004;7(2):97–110. doi:10.1016/j.drup.2004.01.004
   PubMed Web of Science ®Google Scholar
• Benov L. Photodynamic therapy: current status and future directions. Med Princ Pract. 2015;24(Suppl. 1):14–28.
   PubMedGoogle Scholar
• Broekgaarden M, Weijer R, van Gulik TM, Hamblin MR, Heger M. Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies. Cancer Metastasis Rev. 2015;34(4):643–690. doi:10.1007/s10555-015-9588-7
   PubMed Web of Science ®Google Scholar
• Davids LM, Kleemann B. Combating melanoma: the use of photodynamic therapy as a novel, adjuvant therapeutic tool. Cancer Treat Rev. 2011;37(6):465–475. doi:10.1016/j.ctrv.2010.11.007
   PubMed Web of Science ®Google Scholar
• Abrahamse H, Hamblin MR. New photosensitizers for photodynamic therapy. Biochem J. 2018;473(4):347–364.
   Google Scholar
• Almeida RD, Manadas BJ, Carvalho AP. Duarte CB Intracellular signaling mechanisms in photodynamic therapy. Biochim Biophys Acta Rev Cancer. 2004;1704(2):59–86.
   PubMed Web of Science ®Google Scholar
• Kiesslich T, Plaetzer K, Oberdanner CB, Berlanda J, Obermair FJ, Krammer B. Differential effects of glucose deprivation on the cellular sensitivity towards photodynamic treatment-based production of reactive oxygen species and apoptosis-induction. FEBS Lett. 2005;579(1):185–190. doi:10.1016/j.febslet.2004.11.073
   PubMed Web of Science ®Google Scholar
• Kleemann B, Loos B, Scriba TJ, Lang D, Davids LM. St John’s Wort (Hypericum perforatum L.) photomedicine: hypericin-photodynamic therapy induces metastatic melanoma cell death. PLoS One. 2014;9(7):e103762. doi:10.1371/journal.pone.0103762
   PubMed Web of Science ®Google Scholar
• Wyld L, Reed M, Brown N. Differential cell death response to photodynamic therapy is dependent on dose and cell type. Br J Cancer. 2001;84(10):1384. doi:10.1054/bjoc.2001.1795
   PubMed Web of Science ®Google Scholar
• Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagnosis Photodyn Ther. 2004;1(4):279–293. doi:10.1016/S1572-1000(05)00007-4
   PubMed Web of Science ®Google Scholar
• Dąbrowski JM, Arnaut LG, Pereira MM, et al. Combined effects of singlet oxygen and hydroxyl radical in photodynamic therapy with photostable bacteriochlorins: evidence from intracellular fluorescence and increased photodynamic efficacy in vitro. Free Radic Biol Med. 2012;52(7):1188–1200. doi:10.1016/j.freeradbiomed.2011.12.027
   PubMed Web of Science ®Google Scholar
• Ajuwon OR, Marnewick JL, Davids LM. Rooibos (Aspalathus linearis) and its major flavonoids - potential against oxidative stress-induced conditions. In: Gowder S, editor. Basic Principles and Clinical Significance of Oxidative Stress. Rijeka: Intech Europe; 2015:171–218.
   Google Scholar
• Mroz P, Pawlak A, Satti M, et al. Functionalized fullerenes mediate photodynamic killing of cancer cells: type I versus Type II photochemical mechanism. Free Radic Biol Med. 2007;43(5):711–719. doi:10.1016/j.freeradbiomed.2007.05.005
   PubMed Web of Science ®Google Scholar
• Otake E, Sakuma S, Torii K, et al. Effect and mechanism of a new photodynamic therapy with glycoconjugated fullerene. Photochem Photobiol. 2010;86(6):1356–1363. doi:10.1111/j.1751-1097.2010.00790.x
   PubMed Web of Science ®Google Scholar
• Sakharov D, Elstak E, Chernyak B, Wirtz K. Prolonged lipid oxidation after photodynamic treatment. Study with oxidation‐sensitive probe C11‐BODIPY581/591. FEBS Lett. 2005;579(5):1255–1260. doi:10.1016/j.febslet.2005.01.024
   PubMed Web of Science ®Google Scholar
• Valko M, Rhodes C, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160(1):1–40. doi:10.1016/j.cbi.2005.12.009
   PubMed Web of Science ®Google Scholar
• Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44–84. doi:10.1016/j.biocel.2006.07.001
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Dalle‐Donne I. Redox proteomics: from protein modifications to cellular dysfunction and disease. Mass Spectrom Rev. 2014;33(1):1–6. doi:10.1002/mas.21404
   PubMed Web of Science ®Google Scholar
• Baldea I, Olteanu DE, Bolfa P, et al. Efficiency of photodynamic therapy on WM35 melanoma with synthetic porphyrins: role of chemical structure, intracellular targeting and antioxidant defense. J Photochem Photobiol B: Biol. 2015;151:142–152. doi:10.1016/j.jphotobiol.2015.07.019
   PubMed Web of Science ®Google Scholar
• Baldea I, Olteanu DE, Bolfa P, Tabaran F, Ion R-M, Filip GA. Melanogenesis and DNA damage following photodynamic therapy in melanoma with two meso-substituted porphyrins. J Photochem Photobiol B: Biol. 2016;161:402–410. doi:10.1016/j.jphotobiol.2016.06.012
   PubMed Web of Science ®Google Scholar
• Cooke MS, Loft S, Olinski R, et al. Recommendations for standardized description of and nomenclature concerning oxidatively damaged nucleobases in DNA. Chem Res Toxicol. 2010;23(4):705–707. doi:10.1021/tx1000706
   PubMed Web of Science ®Google Scholar
• Al-Mutairi DA, Al-Mutairi DA, Craik JD, Batinic-Haberle I, Benov LT. Induction of oxidative cell damage by photo-treatment with zinc meta N-methylpyridylporphyrin. Free Radic Res. 2007;41(1):89–96. doi:10.1080/10715760600952869
   PubMed Web of Science ®Google Scholar
• Fonda-Pascual P, Moreno-Arrones OM, Alegre-Sanchez A, et al. In situ production of ROS in the skin by photodynamic therapy as a powerful tool in clinical dermatology. Methods. 2016;109:190–202. doi:10.1016/j.ymeth.2016.07.008
   PubMed Web of Science ®Google Scholar
• Buytaert E, Dewaele M, Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta Rev Cancer. 2007;1776(1):86–107. doi:10.1016/j.bbcan.2007.07.001
   PubMed Web of Science ®Google Scholar
• Davids LM, Kleemann B, Kacerovská D, Pizinger K, Kidson SH. Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells. J Photochem Photobiol B: Biol. 2008;91(2):67–76. doi:10.1016/j.jphotobiol.2008.01.011
   PubMed Web of Science ®Google Scholar
• Sparsa A, Bellaton S, Naves T, et al. Photodynamic treatment induces cell death by apoptosis or autophagy depending on the melanin content in two B16 melanoma cell lines. Oncol Rep. 2013;29(3):1196–1200. doi:10.3892/or.2012.2190
   PubMed Web of Science ®Google Scholar
• Buytaert E, Callewaert G, Hendrickx N, et al. Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy. FASEB J. 2006;20(6):756–758. doi:10.1096/fj.05-4305fje
   PubMedGoogle Scholar
• Davids LM, Kleemann B, Cooper S, Kidson SH. Melanomas display increased cytoprotection to hypericin-mediated cytotoxicity through the induction of autophagy. Cell Biol Int. 2009;33(10):1065–1072. doi:10.1016/j.cellbi.2009.06.026
   PubMed Web of Science ®Google Scholar
• Gewirtz DA. Autophagy, senescence and tumor dormancy in cancer therapy. Autophagy. 2009;5(8):1232–1234. doi:10.4161/auto.5.8.9896
   PubMed Web of Science ®Google Scholar
• Lu Z, Luo RZ, Lu Y, et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest. 2008;118(12):3917–3929. doi:10.1172/JCI35512
   PubMed Web of Science ®Google Scholar
• Young AR, Narita M, Ferreira M, et al. Autophagy mediates the mitotic senescence transition. Genes Dev. 2009;23(7):798–803. doi:10.1101/gad.519709
   PubMed Web of Science ®Google Scholar
• Kessel D, Oleinick NL. Initiation of autophagy by photodynamic therapy. Methods Enzymol. 2009;453:1–16.
   PubMed Web of Science ®Google Scholar
• Kessel D, Arroyo AS. Apoptotic and autophagic responses to Bcl-2 inhibition and photodamage. Photochem Photobiol Sci. 2007;6(12):1290–1295. doi:10.1039/b707953b
   PubMed Web of Science ®Google Scholar
• Kessel D, Vicente MGH, Reiners JJ. Initiation of apoptosis and autophagy by photodynamic therapy. Lasers Surg Med. 2006;38(5):482–488. doi:10.1002/lsm.20334
   PubMed Web of Science ®Google Scholar
• Torrente L, DeNicola GM. Targeting NRF2 and its downstream processes: opportunities and challenges. Annu Rev Pharmacol Toxicol. 2022;62:279–300. doi:10.1146/annurev-pharmtox-052220-104025
   PubMed Web of Science ®Google Scholar
• Menegon S, Columbano A, Giordano S. The dual roles of NRF2 in cancer. Trends Mol Med. 2016;22(7):578–593. doi:10.1016/j.molmed.2016.05.002
   PubMed Web of Science ®Google Scholar
• Sánchez-Ortega M, Carrera AC, Garrido A. Role of NRF2 in lung cancer. Cells. 2021;10(8):1879. doi:10.3390/cells10081879
   PubMed Web of Science ®Google Scholar
• Plafker KS, Nguyen L, Barneche M, Mirza S, Crawford D, Plafker SM. The ubiquitin-conjugating enzyme UbcM2 can regulate the stability and activity of the antioxidant transcription factor Nrf2. J Biol Chem. 2010;285(30):23064–23074. doi:10.1074/jbc.M110.121913
   PubMed Web of Science ®Google Scholar
• Telkoparan-Akillilar P, Panieri E, Cevik D, Suzen S, Saso L. Therapeutic targeting of the NRF2 signaling pathway in cancer. Molecules. 2021;26(5):1417. doi:10.3390/molecules26051417
   PubMed Web of Science ®Google Scholar
• Nioi P, Nguyen T, Sherratt PJ, Pickett CB. The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation. Mol Cell Biol. 2005;25(24):10895–10906. doi:10.1128/MCB.25.24.10895-10906.2005
   PubMed Web of Science ®Google Scholar
• Alam MM, Okazaki K, Nguyen LTT, et al. Glucocorticoid receptor signaling represses the antioxidant response by inhibiting histone acetylation mediated by the transcriptional activator NRF2. J Biol Chem. 2017;292(18):7519–7530. doi:10.1074/jbc.M116.773960
   PubMed Web of Science ®Google Scholar
• Katoh Y, Itoh K, Yoshida E, Miyagishi M, Fukamizu A, Yamamoto M. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes Cells. 2001;6(10):857–868. doi:10.1046/j.1365-2443.2001.00469.x
   PubMed Web of Science ®Google Scholar
• Kim JH, Yu S, Chen JD, Kong AN. The nuclear cofactor RAC3/AIB1/SRC-3 enhances Nrf2 signaling by interacting with transactivation domains. Oncogene. 2013;32(4):514–527. doi:10.1038/onc.2012.59
   PubMed Web of Science ®Google Scholar
• Wu T, Zhao F, Gao B, et al. Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis. Genes Dev. 2014;28(7):708–722. doi:10.1101/gad.238246.114
   PubMed Web of Science ®Google Scholar
• Zhang J, Hosoya T, Maruyama A, et al. Nrf2 Neh5 domain is differentially utilized in the transactivation of cytoprotective genes. Biochem J. 2007;404(3):459–466. doi:10.1042/BJ20061611
   PubMedGoogle Scholar
• Chowdhry S, Zhang Y, McMahon M, Sutherland C, Cuadrado A, Hayes JD. Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene. 2013;32(32):3765–3781. doi:10.1038/onc.2012.388
   PubMed Web of Science ®Google Scholar
• Kang JS, Nam LB, Yoo OK, Keum YS. Molecular mechanisms and systemic targeting of NRF2 dysregulation in cancer. Biochem Pharmacol. 2020;177:114002.
   PubMed Web of Science ®Google Scholar
• Wang H, Liu K, Geng M, et al. RXRα inhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 domain of NRF2. Cancer Res. 2013;73(10):3097–3108. doi:10.1158/0008-5472.CAN-12-3386
   PubMed Web of Science ®Google Scholar
• Tebay LE, Robertson H, Durant ST, et al. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radic Biol Med. 2015;88:108–146. doi:10.1016/j.freeradbiomed.2015.06.021
   PubMed Web of Science ®Google Scholar
• Canning P, Cooper CD, Krojer T, et al. Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases. J Biol Chem. 2013;288(11):7803–7814. doi:10.1074/jbc.M112.437996
   PubMed Web of Science ®Google Scholar
• Zipper LM, Mulcahy RT. The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. J Biol Chem. 2002;277(39):36544–36552. doi:10.1074/jbc.M206530200
   PubMed Web of Science ®Google Scholar
• Dinkova-Kostova AT, Holtzclaw WD, Cole RN, et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad of Sci. 2002;99(18):11908–11913. doi:10.1073/pnas.172398899
   PubMed Web of Science ®Google Scholar
• Xie L, Gu Y, Wen M, et al. Hydrogen sulfide induces Keap1 S-sulfhydration and suppresses diabetes-accelerated atherosclerosis via Nrf2 activation. Diabetes. 2016;65(10):3171–3184. doi:10.2337/db16-0020
   PubMed Web of Science ®Google Scholar
• Kopacz A, Kloska D, Forman HJ, Jozkowicz A, Grochot-Przeczek A. Beyond repression of Nrf2: an update on Keap1. Free Radic Biol Med. 2020;157:63–74. doi:10.1016/j.freeradbiomed.2020.03.023
   PubMed Web of Science ®Google Scholar
• Li X, Zhang D, Hannink M, Beamer LJ. Crystal structure of the Kelch domain of human Keap1. J Biol Chem. 2004;279(52):54750–54758. doi:10.1074/jbc.M410073200
   PubMed Web of Science ®Google Scholar
• Ogura T, Tong KI, Mio K, et al. Keap1 is a forked-stem dimer structure with two large spheres enclosing the intervening, double glycine repeat, and C-terminal domains. Proc Natl Acad Sci. 2010;107(7):2842–2847. doi:10.1073/pnas.0914036107
   PubMed Web of Science ®Google Scholar
• Espinosa-Diez C, Miguel V, Mennerich D, et al. Antioxidant responses and cellular adjustments to oxidative stress. Redox Biol. 2015;6:183–197. doi:10.1016/j.redox.2015.07.008
   PubMed Web of Science ®Google Scholar
• Furfaro A, Traverso N, Domenicotti C, et al. The Nrf2/HO-1 axis in cancer cell growth and chemoresistance. Oxid Med Cell Longev. 2016;2016:1958174. doi:10.1155/2016/1958174
   PubMed Web of Science ®Google Scholar
• Milkovic L, Zarkovic N, Saso L. Controversy about pharmacological modulation of Nrf2 for cancer therapy. Redox Biol. 2017;12:727–732. doi:10.1016/j.redox.2017.04.013
   PubMed Web of Science ®Google Scholar
• Bryan HK, Olayanju A, Goldring CE, Park BK. The Nrf2 cell defence pathway: keap1-dependent and-independent mechanisms of regulation. Biochem Pharmacol. 2013;85(6):705–717. doi:10.1016/j.bcp.2012.11.016
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Inoue Y, Ikegami Y, et al. A new strategy of ALA-photodynamic cancer therapy: inhibition of ABC transporter ABCG2. In: Efferth T, editor. Resistance to Targeted ABC Transporters in Cancer. Cham: Springer International Publishing; 2015:89–104.
   Google Scholar
• Egea J, González-Rodríguez Á, Gómez-Guerrero C, Moreno JA. Role of Nrf2 in disease: novel molecular mechanisms and therapeutic approaches. Front Pharmacol. 2019;10:1149. doi:10.3389/fphar.2019.01149
   PubMed Web of Science ®Google Scholar
• Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer. 2012;12(8):564–571. doi:10.1038/nrc3278
   PubMed Web of Science ®Google Scholar
• Dinkova-Kostova AT, Jenkins SN, Fahey JW, et al. Protection against UV-light-induced skin carcinogenesis in SKH-1 high-risk mice by sulforaphane-containing broccoli sprout extracts. Cancer Lett. 2006;240(2):243–252. doi:10.1016/j.canlet.2005.09.012
   PubMed Web of Science ®Google Scholar
• Fahey JW, Haristoy X, Dolan PM, et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo [a] pyrene-induced stomach tumors. Proc Natl Acad Sci. 2002;99(11):7610–7615. doi:10.1073/pnas.112203099
   PubMed Web of Science ®Google Scholar
• Gills JJ, Jeffery EH, Matusheski NV, Moon RC, Lantvit DD, Pezzuto JM. Sulforaphane prevents mouse skin tumorigenesis during the stage of promotion. Cancer Lett. 2006;236(1):72–79. doi:10.1016/j.canlet.2005.05.007
   PubMed Web of Science ®Google Scholar
• Liby KT, Royce DB, Risingsong R, et al. Synthetic Triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prev Res. 2010;3(11):1427–1434. doi:10.1158/1940-6207.CAPR-10-0197
   PubMed Web of Science ®Google Scholar
• Kim EH, Deng C, Sporn MB, et al. CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice. Cancer Prev Res. 2012;5(1):89–97. doi:10.1158/1940-6207.CAPR-11-0359
   PubMed Web of Science ®Google Scholar
• Aoki Y, Sato H, Nishimura N, Takahashi S, Itoh K, Yamamoto M. Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol Appl Pharmacol. 2001;173(3):154–160. doi:10.1006/taap.2001.9176
   PubMed Web of Science ®Google Scholar
• Iida K, Itoh K, Maher JM, et al. Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis. Carcinogenesis. 2007;28(11):2398–2403. doi:10.1093/carcin/bgm146
   PubMed Web of Science ®Google Scholar
• Iizuka T, Ishii Y, Itoh K, et al. Nrf2‐deficient mice are highly susceptible to cigarette smoke‐induced emphysema. Genes Cells. 2005;10(12):1113–1125. doi:10.1111/j.1365-2443.2005.00905.x
   PubMed Web of Science ®Google Scholar
• Kitamura Y, Umemura T, Kanki K, et al. Increased susceptibility to hepatocarcinogenicity of Nrf2‐deficient mice exposed to 2‐amino‐3‐methylimidazo [4, 5‐f] quinoline. Cancer Sci. 2007;98(1):19–24. doi:10.1111/j.1349-7006.2006.00352.x
   PubMed Web of Science ®Google Scholar
• Khor TO, Huang MT, Prawan A, et al. Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer. Cancer Prev Res. 2008;1(3):187–191. doi:10.1158/1940-6207.CAPR-08-0028
   PubMed Web of Science ®Google Scholar
• Iida K, Itoh K, Kumagai Y, et al. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res. 2004;64(18):6424–6431. doi:10.1158/0008-5472.CAN-04-1906
   PubMed Web of Science ®Google Scholar
• Ramos-Gomez M, Kwak M-K, Dolan PM, et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in Nrf2 transcription factor-deficient mice. Proc Natl Acad Sci. 2001;98(6):3410–3415. doi:10.1073/pnas.051618798
   PubMed Web of Science ®Google Scholar
• Xu C, Huang MT, Shen G, et al. Inhibition of 7, 12-dimethylbenz (a) anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2–related factor 2. Cancer Res. 2006;66(16):8293–8296. doi:10.1158/0008-5472.CAN-06-0300
   PubMed Web of Science ®Google Scholar
• Yates MS, Kwak MK, Egner PA, et al. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-, 12-dioxooleana-1, 9 (11)-dien-28-oyl] imidazole. Cancer Res. 2006;66(4):2488–2494. doi:10.1158/0008-5472.CAN-05-3823
   PubMed Web of Science ®Google Scholar
• Satoh H, Moriguchi T, Taguchi K, et al. Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis. 2010;31(10):1833–1843. doi:10.1093/carcin/bgq105
   PubMed Web of Science ®Google Scholar
• Suzuki T, Shibata T, Takaya K, et al. Regulatory nexus of synthesis and degradation deciphers cellular Nrf2 expression levels. Mol Cell Biol. 2013;33(12):2402–2412. doi:10.1128/MCB.00065-13
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Yoh K, Kobayashi A, et al. Identification of polymorphisms in the promoter region of the human NRF2 gene. Biochem Biophys Res Commun. 2004;321(1):72–79. doi:10.1016/j.bbrc.2004.06.112
   PubMed Web of Science ®Google Scholar
• Gañán-Gómez I, Wei Y, Yang H, Boyano-Adánez MC, García-Manero G. Oncogenic functions of the transcription factor Nrf2. Free Radic Biol Med. 2013;65:750–764. doi:10.1016/j.freeradbiomed.2013.06.041
   PubMed Web of Science ®Google Scholar
• Homma S, Ishii Y, Morishima Y, et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res. 2009;15(10):3423–3432. doi:10.1158/1078-0432.CCR-08-2822
   PubMed Web of Science ®Google Scholar
• H-K N, Surh Y-J. Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. Free Radic Biol Med. 2014;67:353–365. doi:10.1016/j.freeradbiomed.2013.10.819
   PubMed Web of Science ®Google Scholar
• Niture SK, Jaiswal AK. Nrf2-induced antiapoptotic Bcl-xL protein enhances cell survival and drug resistance. Free Radic Biol Med. 2013;57:119–131. doi:10.1016/j.freeradbiomed.2012.12.014
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Spentzos D, Fountzilas E, et al. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res. 2011;71(15):5081–5089. doi:10.1158/0008-5472.CAN-10-4668
   PubMed Web of Science ®Google Scholar
• Solis LM, Behrens C, Dong W, et al. Nrf2 and Keap1 abnormalities in non–small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res. 2010;16(14):3743–3753. doi:10.1158/1078-0432.CCR-09-3352
   PubMed Web of Science ®Google Scholar
• Torrente L, Maan G, Oumkaltoum Rezig A, et al. High NRF2 levels correlate with poor prognosis in colorectal cancer patients and with sensitivity to the kinase inhibitor AT9283 in vitro. Biomolecules. 2020;10(10):1365. doi:10.3390/biom10101365
   PubMed Web of Science ®Google Scholar
• Ohta T, Iijima K, Miyamoto M, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 2008;68(5):1303–1309. doi:10.1158/0008-5472.CAN-07-5003
   PubMed Web of Science ®Google Scholar
• Padmanabhan B, Tong KI, Ohta T, et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell. 2006;21(5):689–700. doi:10.1016/j.molcel.2006.01.013
   PubMed Web of Science ®Google Scholar
• Fujimoto A, Furuta M, Totoki Y, et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet. 2016;48(5):500–509. doi:10.1038/ng.3547
   PubMed Web of Science ®Google Scholar
• Shibata T, Kokubu A, Gotoh M, et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology. 2008;135(4):1358–1368. doi:10.1053/j.gastro.2008.06.082
   PubMed Web of Science ®Google Scholar
• Nioi P, Nguyen T. A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem Biophys Res Commun. 2007;362(4):816–821. doi:10.1016/j.bbrc.2007.08.051
   PubMed Web of Science ®Google Scholar
• Yoo NJ, Kim HR, Kim YR, An CH, Lee SH. Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology. 2012;60(6):943–952. doi:10.1111/j.1365-2559.2012.04178.x
   PubMed Web of Science ®Google Scholar
• Kim YR, Oh JE, Kim MS, et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol. 2010;220(4):446–451. doi:10.1002/path.2653
   PubMed Web of Science ®Google Scholar
• Wong TF, Yoshinaga K, Monma Y, et al. Association of Keap1 and Nrf2 genetic mutations and polymorphisms with endometrioid endometrial adenocarcinoma survival. Int J Gynecol Cancer. 2011;21(8):1428–1435. doi:10.1097/IGC.0b013e31822d0eb2
   PubMed Web of Science ®Google Scholar
• Li QK, Singh A, Biswal S, Askin F, Gabrielson E. KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma. J Hum Genet. 2011;56(3):230–234. doi:10.1038/jhg.2010.172
   PubMed Web of Science ®Google Scholar
• Mitsuishi Y, Taguchi K, Kawatani Y, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 2012;22(1):66–79. doi:10.1016/j.ccr.2012.05.016
   PubMed Web of Science ®Google Scholar
• Lister A, Nedjadi T, Kitteringham NR, et al. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer. 2011;10(1):1–13. doi:10.1186/1476-4598-10-37
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang C, Zhang L, et al. Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma. BMC Cancer. 2015;15(1):1–12. doi:10.1186/s12885-015-1541-1
   PubMedGoogle Scholar
• Zhang C, Wang HJ, Bao QC, et al. NRF2 promotes breast cancer cell proliferation and metastasis by increasing RhoA/ROCK pathway signal transduction. Oncotarget. 2016;7(45):73593. doi:10.18632/oncotarget.12435
   PubMedGoogle Scholar
• DeNicola GM, Karreth FA, Humpton TJ, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011;475(7354):7354):106–109. doi:10.1038/nature10189
   Web of Science ®Google Scholar
• Murakami S, Motohashi H. Roles of Nrf2 in cell proliferation and differentiation. Free Radic Biol Med. 2015;88:168–178. doi:10.1016/j.freeradbiomed.2015.06.030
   PubMed Web of Science ®Google Scholar
• Rojo AI, Rada P, Mendiola M, et al. The PTEN/NRF2 axis promotes human carcinogenesis. Antioxid Redox Signal. 2014;21(18):2498–2514. doi:10.1089/ars.2014.5843
   PubMed Web of Science ®Google Scholar
• Faraonio R, Vergara P, Di Marzo D, et al. p53 suppresses the Nrf2‐dependent transcription of antioxidant response genes. J Biol Chem. 2006;281(52):39776‐39784. doi:10.1074/jbc.M605707200
   PubMed Web of Science ®Google Scholar
• Elsby R, Kitteringham NR, Goldring CE, et al. Increased constitutive c‐Jun N‐terminal kinase signaling in mice lacking glutathione S‐transferase Pi. J Biol Chem. 2003;278(25):22243‐22249. doi:10.1074/jbc.M301211200
   PubMed Web of Science ®Google Scholar
• Jain A, Lamark T, Sjottem E, et al. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element‐driven gene transcription. J Biol Chem. 2010;285(29):22576‐22591. doi:10.1074/jbc.M110.118976
   Web of Science ®Google Scholar
• Niture SK, Jaiswal AK. Nrf2 protein up‐regulates antiapoptotic protein Bcl‐2 and prevents cellular apoptosis. J Biol Chem. 2012;287(13):9873‐9886. doi:10.1074/jbc.M111.312694
   PubMed Web of Science ®Google Scholar
• Arfmann-Knübel S, Struck B, Genrich G, et al. The crosstalk between Nrf2 and TGF-β1 in the epithelial-mesenchymal transition of pancreatic duct epithelial cells. PLoS One. 2015;10(7):e0132978. doi:10.1371/journal.pone.0132978
   PubMed Web of Science ®Google Scholar
• Zhao Q, Mao A, Guo R, et al. Suppression of radiation-induced migration of non-small cell lung cancer through inhibition of Nrf2-Notch axis. Oncotarget. 2017;8(22):36603. doi:10.18632/oncotarget.16622
   PubMedGoogle Scholar
• Lignitto L, LeBoeuf SE, Homer H, et al. Nrf2 activation promotes lung cancer metastasis by inhibiting the degradation of Bach1. Cell. 2019;178(2):316–329. doi:10.1016/j.cell.2019.06.003
   PubMed Web of Science ®Google Scholar
• Shen H, Yang Y, Xia S, Rao B, Zhang J, Wang J. Blockage of Nrf2 suppresses the migration and invasion of esophageal squamous cell carcinoma cells in hypoxic microenvironment. Dis Esophagus. 2014;27(7):685–692. doi:10.1111/dote.12124
   PubMed Web of Science ®Google Scholar
• Frohlich DA, McCabe MT, Arnold RS, Day ML. The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. Oncogene. 2008;27(31):4353–4362. doi:10.1038/onc.2008.79
   PubMed Web of Science ®Google Scholar
• Rachakonda G, Sekhar KR, Jowhar D, et al. Increased cell migration and plasticity in Nrf2-deficient cancer cell lines. Oncogene. 2010;29(25):3703–3714. doi:10.1038/onc.2010.118
   PubMed Web of Science ®Google Scholar
• Ryu D, Lee JH, Kwak MK. NRF2 level is negatively correlated with TGF-β1-induced lung cancer motility and migration via NOX4-ROS signaling. Arch Pharm Res. 2020;43(12):1297–1310. doi:10.1007/s12272-020-01298-z
   PubMed Web of Science ®Google Scholar
• Wang XJ, Sun Z, Villeneuve NF, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis. 2008;29(6):1235–1243. doi:10.1093/carcin/bgn095
   PubMed Web of Science ®Google Scholar
• Shim GS, Manandhar S, Shin DH, Kim TH, Kwak MK. Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radic Biol Med. 2009;47(11):1619–1631. doi:10.1016/j.freeradbiomed.2009.09.006
   PubMed Web of Science ®Google Scholar
• Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1–NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006;3(10):e420. doi:10.1371/journal.pmed.0030420
   PubMed Web of Science ®Google Scholar
• Kalyanaraman B, Cheng G, Hardy M, Ouari O, Bennett B, Zielonka J. Teaching the basics of reactive oxygen species and their relevance to cancer biology: mitochondrial reactive oxygen species detection, redox signaling, and targeted therapies. Redox Biol. 2018;15:347–362. doi:10.1016/j.redox.2017.12.012
   PubMed Web of Science ®Google Scholar
• Parascandolo A, Laukkanen MO. Carcinogenesis and reactive oxygen species signaling: interaction of the NADPH oxidase NOX1–5 and superoxide dismutase 1–3 signal transduction pathways. Antioxid Redox Signal. 2019;30(3):443–486. doi:10.1089/ars.2017.7268
   PubMed Web of Science ®Google Scholar
• Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991;51(3):794–798.
   PubMed Web of Science ®Google Scholar
• Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. FEBS Lett. 1995;358(1):1–3. doi:10.1016/0014-5793(94)01368-B
   PubMed Web of Science ®Google Scholar
• Liu C, Zhao Y, Wang J, et al. FoxO3 reverses 5-fluorouracil resistance in human colorectal cancer cells by inhibiting the Nrf2/TR1 signaling pathway. Cancer Lett. 2020;470:29–42. doi:10.1016/j.canlet.2019.11.042
   PubMed Web of Science ®Google Scholar
• Barrera G, Cucci MA, Grattarola M, Dianzani C, Muzio G, Pizzimenti S. Control of oxidative stress in cancer chemoresistance: spotlight on Nrf2 role. Antioxidants. 2021;10(4):510. doi:10.3390/antiox10040510
   Web of Science ®Google Scholar
• Hospers GAP, Meuer C, De Leij L, Uges DRA, Mulder NH, De Vries EGE. A study of human small‐cell lung carcinoma (hSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (CDDP) resistance. Int, J, Cancer. 1990;46(1):138–144. doi:10.1002/ijc.2910460125
   PubMed Web of Science ®Google Scholar
• Jain N, Lam YM, Pym J, Campling BG. Mechanisms of resistance of human small cell lung cancer lines selected in VP‐16 and cisplatin. Cancer. 1996;77(9):1797–1808. doi:10.1002/(SICI)1097-0142(19960501)77:9<1797::AID-CNCR7>3.0.CO;2-9
   PubMed Web of Science ®Google Scholar
• Kim SK, Yang JW, Kim MR, et al. Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free Radic Biol Med. 2008;45(4):537–546. doi:10.1016/j.freeradbiomed.2008.05.011
   PubMed Web of Science ®Google Scholar
• Shibata T, Kokubu A, Saito S, et al. NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia. 2011;13(9):864–873. doi:10.1593/neo.11750
   PubMed Web of Science ®Google Scholar
• Chian S, Li YY, Wang XJ, Tang XW. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway. Asian Pac J Cancer Prev. 2014;15(6):2911–2916. doi:10.7314/APJCP.2014.15.6.2911
   PubMed Web of Science ®Google Scholar
• Duong HQ, Yi YW, Kang HJ, et al. Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. Int J Oncol. 2014;44(3):959–969. doi:10.3892/ijo.2013.2229
   PubMed Web of Science ®Google Scholar
• Hou X, Bai X, Gou X, et al. 3′, 4′, 5′, 5, 7-pentamethoxyflavone sensitizes cisplatin-resistant A549 cells to cisplatin by inhibition of Nrf2 pathway. Mol Cells. 2015;38(5):396–401. doi:10.14348/molcells.2015.2183
   PubMed Web of Science ®Google Scholar
• Zhong Y, Zhang F, Sun Z, et al. Drug resistance associates with activation of Nrf2 in MCF‐7/DOX cells, and wogonin reverses it by down‐regulating Nrf2‐mediated cellular defense response. Mol, Carcinog. 2013;52(10):824–834. doi:10.1002/mc.21921
   PubMed Web of Science ®Google Scholar
• Huang J, Tan PH, Thiyagarajan J, Bay BH. Prognostic significance of glutathione-S-transferase-pi in invasive breast cancer. Mod Pathol. 2003;16(6):558–565. doi:10.1097/01.MP.0000071842.83169.5A
   PubMed Web of Science ®Google Scholar
• Su F, Hu X, Jia W, Gong C, Song E, Hamar P. Glutathion-s-transferase π indicates chemotherapy resistance in breast cancer. J Surg Res. 2003;113(1):102–108. doi:10.1016/S0022-4804(03)00200-2
   PubMed Web of Science ®Google Scholar
• Chen B, Shen Z, Wu D, et al. Glutathione peroxidase 1 promotes NSCLC resistance to cisplatin via ROS-induced activation of PI3K/AKT pathway. BioMed Res Int. 2019;2019:7640547. doi:10.1155/2019/7640547
   PubMed Web of Science ®Google Scholar
• Du H, Chen B, Jiao NL, Liu YH, Sun SY, Zhang YW. Elevated glutathione peroxidase 2 expression promotes cisplatin resistance in lung adenocarcinoma. Oxid Med Cell Longev. 2020;2020:7370157. doi:10.1155/2020/7370157
   PubMed Web of Science ®Google Scholar
• Zarei M, Lal S, Parker SJ, et al. Posttranscriptional upregulation of IDH1 by HuR establishes a powerful survival phenotype in pancreatic cancer cells. Cancer Res. 2017;77(16):4460–4471. doi:10.1158/0008-5472.CAN-17-0015
   PubMed Web of Science ®Google Scholar
• Patel GK, Khan MA, Bhardwaj A, et al. Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. Br J Cancer. 2017;116(5):609–619. doi:10.1038/bjc.2017.18
   PubMed Web of Science ®Google Scholar
• Cho JM, Manandhar S, Lee HR, Park HM, Kwak MK. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett. 2008;260(1–2):96–108. doi:10.1016/j.canlet.2007.10.022
   PubMed Web of Science ®Google Scholar
• Zhang P, Singh A, Yegnasubramanian S, et al. Loss of Kelch-Like ECH-Associated Protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther. 2010;9(2):336–346. doi:10.1158/1535-7163.MCT-09-0589
   PubMed Web of Science ®Google Scholar
• Tang X, Wang H, Fan L, et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med. 2011;50(11):1599–1609. doi:10.1016/j.freeradbiomed.2011.03.008
   PubMed Web of Science ®Google Scholar
• Benderra Z, Faussat AM, Sayada L, et al. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res. 2005;11(21):7764–7772. doi:10.1158/1078-0432.CCR-04-1895
   PubMed Web of Science ®Google Scholar
• Khot MI, Downey CL, Armstrong G, et al. The role of ABCG2 in modulating responses to anti-cancer photodynamic therapy. Photodiagnosis Photodyn Ther. 2020;29:101579. doi:10.1016/j.pdpdt.2019.10.014
   PubMed Web of Science ®Google Scholar
• Loignon M, Miao W, Hu L, et al. Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy. Mol Cancer Ther. 2009;8(8):2432–2440. doi:10.1158/1535-7163.MCT-08-1186
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang Y, Li W, et al. Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway. Biochem Pharmacol. 2014;92(2):220–234. doi:10.1016/j.bcp.2014.09.008
   PubMed Web of Science ®Google Scholar
• Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res. 2001;7(6):1798–1804.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Sanchez E, Marin JJ, Perez MJ. The expression of genes involved in hepatocellular carcinoma chemoresistance is affected by mitochondrial genome depletion. Mol Pharm. 2014;11(6):1856–1868. doi:10.1021/mp400732p
   PubMedGoogle Scholar
• de Souza I, Monteiro LKS, Guedes CB, et al. High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1/MRP1 upregulation. Cell Death Dis. 2022;13(7):1–13. doi:10.1038/s41419-022-05044-9
   Web of Science ®Google Scholar
• Choi HK, Yang JW, Roh SH, Han CY, Kang KW. Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer. 2007;14(2):293–303. doi:10.1677/ERC-06-0016
   PubMed Web of Science ®Google Scholar
• Materna V, Liedert B, Thomale J, Lage H. Protection of platinum–DNA adduct formation and reversal of cisplatin resistance by anti‐MRP2 hammerhead ribozymes in human cancer cells. Int, J, Cancer. 2005;115(3):393–402. doi:10.1002/ijc.20899
   PubMed Web of Science ®Google Scholar
• Paramasivan P, Kankia IH, Langdon SP, Deeni YY. Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies. Cancer Drug Resist. 2019;2(3):490–515. doi:10.20517/cdr.2019.57
   PubMedGoogle Scholar
• Zhang L, Fang CH, Fan YF. Detection of multidrug resistance-associated proteins MRP2, MRP3, and MRP5 mRNA expressions in hepatocarcinoma cells using SYBR real-time PCR. J South Med Univ. 2008;28(2):219–221.
   Google Scholar
• Zhang YH, Wu Q, Xiao XY, Li DW, Wang XP. Silencing MRP4 by small interfering RNA reverses acquired DDP resistance of gastric cancer cell. Cancer Lett. 2010;291(1):76–82. doi:10.1016/j.canlet.2009.10.003
   PubMed Web of Science ®Google Scholar
• Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003;22(47):7340–7358. doi:10.1038/sj.onc.1206938
   PubMed Web of Science ®Google Scholar
• Yuan J, Lv H, Peng B, Wang C, Yu Y, He Z. Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009;63(6):1103–1110. doi:10.1007/s00280-008-0838-z
   PubMed Web of Science ®Google Scholar
• Wu CP, Sim HM, Huang YH, et al. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF (V600E) mutant cancer cells. Biochem Pharmacol. 2013;85(3):325–334. doi:10.1016/j.bcp.2012.11.003
   PubMed Web of Science ®Google Scholar
• Singh A, Wu H, Zhang P, Happel C, Ma J, Biswal S. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol Cancer Ther. 2010;9(8):2365–2376. doi:10.1158/1535-7163.MCT-10-0108
   PubMed Web of Science ®Google Scholar
• Kim EJ, Kim YJ, Lee HI, Jeong SH, Nam HJ, Cho JH. NRF2 knockdown resensitizes 5-fluorouracil-resistant pancreatic cancer cells by suppressing HO-1 and ABCG2 expression. Int J Mol Sci. 2020;21(13):4646. doi:10.3390/ijms21134646
   PubMed Web of Science ®Google Scholar
• Liao W, Wang Z, Fu Z, et al. p62/SQSTM1 protects against cisplatin-induced oxidative stress in kidneys by mediating the cross talk between autophagy and the Keap1-Nrf2 signalling pathway. Free Radic Res. 2019;53(7):800–814. doi:10.1080/10715762.2019.1635251
   PubMed Web of Science ®Google Scholar
• Mirzaei S, Mohammadi AT, Gholami MH, et al. Nrf2 signaling pathway in cisplatin chemotherapy: potential involvement in organ protection and chemoresistance. Pharmacol Res. 2021;167:105575. doi:10.1016/j.phrs.2021.105575
   PubMed Web of Science ®Google Scholar
• Kocanova S, Buytaert E, Matroule J-Y, et al. Induction of heme-oxygenase 1 requires the p38MAPK and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy. Apoptosis. 2007;12(4):731–741. doi:10.1007/s10495-006-0016-x
   PubMed Web of Science ®Google Scholar
• Ajuwon OR, Lawal AO, Marnewick JL, Davids LM The transcription factor Nrf2 mediates endogenous antioxidants upregulation in response to hypericin-photodynamic therapy in melanoma cells. Poster presented at: Oxygen Club of California World Congress; May 4-6; 2016; University of California, Davis; CA.
   Google Scholar
• Dolgachev V, Oberley LW, Huang -T-T, et al. A role for manganese superoxide dismutase in apoptosis after photosensitization. Biochem Biophys Res Commun. 2005;332(2):411–417. doi:10.1016/j.bbrc.2005.04.141
   PubMed Web of Science ®Google Scholar
• Nowis D, Legat M, Grzela T, et al. Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene. 2006;25(24):3365–3374. doi:10.1038/sj.onc.1209378
   PubMed Web of Science ®Google Scholar
• Wang HP, Qian SY, Schafer FQ, Domann FE, Oberley LW, Buettner GR. Phospholipid hydroperoxide glutathione peroxidase protects against singlet oxygen-induced cell damage of photodynamic therapy. Free Radic Biol Med. 2001;30(8):825–835. doi:10.1016/S0891-5849(01)00469-5
   PubMed Web of Science ®Google Scholar
• Aniogo EC, George BP, Abrahamse H. Molecular effectors of photodynamic therapy-mediated resistance to cancer cells. Int J Mol Sci. 2021;22(24):13182. doi:10.3390/ijms222413182
   PubMed Web of Science ®Google Scholar
• Mastrangelopoulou M, Grigalavicius M, Raabe TH, et al. Predictive biomarkers for 5‐ALA‐PDT can lead to personalized treatments and overcome tumor‐specific resistances. Cancer Rep. 2022;5(12):e1278.
   Google Scholar
• Dabrowski MJ, Maeda D, Zebala J, et al. Glutathione S-transferase P1-1 expression modulates sensitivity of human kidney 293 cells to photodynamic therapy with hypericin. Arch Biochem Biophys. 2006;449(1–2):94–103. doi:10.1016/j.abb.2006.02.009
   PubMed Web of Science ®Google Scholar
• Tian S, Yong M, Zhu J, et al. Enhancement of the effect of methyl pyropheophorbide-a-mediated photodynamic therapy was achieved by increasing ROS through inhibition of Nrf2-HO-1 or Nrf2-ABCG2 signaling. Anticancer Agents Med Chem. 2017;17(13):1824–1836. doi:10.2174/1871520617666170327145857
   PubMed Web of Science ®Google Scholar
• Choi BH, Ryoo IG, Kang HC, Kwak MK. The sensitivity of cancer cells to pheophorbide a-based photodynamic therapy is enhanced by Nrf2 silencing. PLoS One. 2014;9(9):e107158. doi:10.1371/journal.pone.0107158
   PubMed Web of Science ®Google Scholar
• Ferino A, Rapozzi V, Xodo LE. The ROS-KRAS-Nrf2 axis in the control of the redox homeostasis and the intersection with survival-apoptosis pathways: implications for photodynamic therapy. J Photochem Photobiol B: Biol. 2020;202:111672. doi:10.1016/j.jphotobiol.2019.111672
   PubMed Web of Science ®Google Scholar
• Kimani SG, Phillips JB, Bruce JI, MacRobert AJ, Golding JP. Antioxidant inhibitors potentiate the cytotoxicity of photodynamic therapy. Photochem Photobiol. 2012;88(1):175–187. doi:10.1111/j.1751-1097.2011.01022.x
   PubMed Web of Science ®Google Scholar
• Theodossiou TA, Olsen CE, Jonsson M, Kubin A, Hothersall JS, Berg K. The diverse roles of glutathione-associated cell resistance against hypericin photodynamic therapy. Redox Biol. 2017;12:191–197. doi:10.1016/j.redox.2017.02.018
   PubMed Web of Science ®Google Scholar
• Lin T, Zhao X, Zhao S, et al. O2-generating MnO2 nanoparticles for enhanced photodynamic therapy of bladder cancer by ameliorating hypoxia. Theranostics. 2018;8(4):990–1004. doi:10.7150/thno.22465
   PubMed Web of Science ®Google Scholar
• Liu C, Wang D, Zhang S, et al. Biodegradable biomimic copper/manganese silicate nanospheres for chemodynamic/photodynamic synergistic therapy with simultaneous glutathione depletion and hypoxia relief. ACS Nano. 2019;13(4):4267–4277. doi:10.1021/acsnano.8b09387
   PubMed Web of Science ®Google Scholar
• Wang C, Cao F, Ruan Y, Jia X, Zhen W, Jiang X. Specific generation of singlet oxygen through the Russell mechanism in hypoxic tumors and GSH depletion by Cu‐TCPP nanosheets for cancer therapy. Angew Chem. 2019;131(29):9951–9955. doi:10.1002/ange.201903981
   Google Scholar
• Zhang Y, Li S, Fang X, et al. Copper decorated Ti3C2 nanosystem with NIR-II-induced GSH-depletion and reactive oxygen species generation for efficient nanodynamic therapy. Nanophotonics. 2022;11(22):5189–5204. doi:10.1515/nanoph-2022-0599
   Web of Science ®Google Scholar
• Frank J, Lornejad-Schafer M, Schoffl H, Flaccus A, Lambert C, Biesalski HK. Inhibition of heme oxygenase-1 increases responsiveness of melanoma cells to ALA-based photodynamic therapy. Int J Oncol. 2007;31(6):1539–1545.
   PubMed Web of Science ®Google Scholar
• Miyake M, Ishii M, Kawashima K, et al. siRNA‐mediated knockdown of the heme synthesis and degradation pathways: modulation of treatment effect of 5‐aminolevulinic acid‐based photodynamic therapy in urothelial cancer cell lines. Photochem Photobiol. 2009;85(4):1020–1027. doi:10.1111/j.1751-1097.2009.00543.x
   PubMed Web of Science ®Google Scholar
• Kimakova P, Solar P, Feckova B, et al. Photoactivated hypericin increases the expression of SOD-2 and makes MCF-7 cells resistant to photodynamic therapy. Biomed Pharmacother. 2017;85:749–755. doi:10.1016/j.biopha.2016.11.093
   PubMed Web of Science ®Google Scholar
• Ğb JG, Nowis D, Skrzycki M, et al. Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol: a superoxide dismutase inhibitor. J Biol Chem. 2003;278(1):407–414. doi:10.1074/jbc.M209125200
   PubMed Web of Science ®Google Scholar
• Wright KE, MacRobert AJ, Phillips JB. Inhibition of specific cellular antioxidant pathways increases the sensitivity of neurons to meta‐tetrahydroxyphenyl chlorin‐mediated photodynamic therapy in a 3D co‐culture model. Photochem Photobiol. 2012;88(6):1539–1545. doi:10.1111/j.1751-1097.2012.01185.x
   PubMed Web of Science ®Google Scholar
• Hamblin MR. Drug efflux pumps in photodynamic therapy. In: Sosnik A, Bendayan R, editors. Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy. Cambridge, Massachusetts: Academic Press; 2020:251–276.
   Google Scholar
• Robey RW, Steadman K, Polgar O, Bates SE. ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol Ther. 2005;4(2):195–202. doi:10.4161/cbt.4.2.1440
   PubMed Web of Science ®Google Scholar
• Hagiya Y, Adachi T, Ogura S-I, et al. Nrf2-dependent induction of human ABC transporter ABCG2 and heme oxygenase-1 in HepG2 cells by photoactivation of porphyrins: biochemical implications for cancer cell response to photodynamic therapy. J Exp Ther Oncol. 2008;7(2):153–167.
   PubMedGoogle Scholar
• Liu W, Baer MR, Bowman MJ, et al. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res. 2007;13(8):2463–2470. doi:10.1158/1078-0432.CCR-06-1599
   PubMed Web of Science ®Google Scholar
• Sun W, Kajimoto Y, Inoue H, Miyatake SI, Ishikawa T, Kuroiwa T. Gefitinib enhances the efficacy of photodynamic therapy using 5-aminolevulinic acid in malignant brain tumor cells. Photodiagnosis Photodyn Ther. 2013;10(1):42–50. doi:10.1016/j.pdpdt.2012.06.003
   PubMed Web of Science ®Google Scholar
• Kim JH, Park JM, Roh YJ, Kim IW, Hasan T, Choi MG. Enhanced efficacy of photodynamic therapy by inhibiting ABCG2 in colon cancers. BMC Cancer. 2015;15(1):1–9. doi:10.1186/s12885-015-1514-4
   PubMedGoogle Scholar
• Jung KA, Choi BH, Kwak MK. The c-MET/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP/ABCG2 expression. Mol Pharmacol. 2015;87(3):465–476. doi:10.1124/mol.114.096065
   PubMed Web of Science ®Google Scholar
• Jendželovský R, Mikeš J, Souček K, et al. Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells. Photochem Photobiol Sci. 2009;8(12):1716–1723. doi:10.1039/b9pp00086k
   PubMed Web of Science ®Google Scholar
• Jendželovský R, Jendželovská Z, Kucharova B, Fedoročko P. Breast cancer resistance protein is the enemy of hypericin accumulation and toxicity of hypericin-mediated photodynamic therapy. Biomed Pharmacother. 2019;109:2173–2181. doi:10.1016/j.biopha.2018.11.084
   PubMed Web of Science ®Google Scholar
• Khot MI, Perry SL, Maisey T, et al. Inhibiting ABCG2 could potentially enhance the efficacy of hypericin-mediated photodynamic therapy in spheroidal cell models of colorectal cancer. Photodiagnosis Photodyn Ther. 2018;23:221–229. doi:10.1016/j.pdpdt.2018.06.027
   PubMed Web of Science ®Google Scholar
• Kuchárová B, Mikeš J, Jendželovský R, et al. Potentiation of hypericin-mediated photodynamic therapy cytotoxicity by MK-886: focus on ABC transporters, GDF-15 and redox status. Photodiagnosis Photodyn Ther. 2015;12(3):490–503. doi:10.1016/j.pdpdt.2015.04.008
   PubMed Web of Science ®Google Scholar
• Biteghe FN, Davids LM. A combination of photodynamic therapy and chemotherapy displays a differential cytotoxic effect on human metastatic melanoma cells. J Photochem Photobiol B: Biol. 2017;166:18–27. doi:10.1016/j.jphotobiol.2016.11.004
   PubMed Web of Science ®Google Scholar